Admin Suppl Gender-affirming estrogen therapy and breast cancer treatment outcome
行政补充性别肯定雌激素治疗和乳腺癌治疗结果
基本信息
- 批准号:10783533
- 负责人:
- 金额:$ 8.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAgeBenefits and RisksBiological AssayBody ImageBreastBreast Cancer ModelBreast Cancer TreatmentCancer PrognosisClinicalCommunitiesComplementDiagnosisEstrogen TherapyEstrogen receptor negativeEstrogen receptor positiveFemaleFeminineGenderGoalsGonadal Steroid HormonesGrantGuidelinesHistologyImmuneImmunofluorescence ImmunologicIndividualKnowledgeMass Spectrum AnalysisMeasuresMedicalModelingMolecularMusParentsPatient riskPatientsPopulationStainsTreatment outcomeWell in selfWorkalpelisibassigned male at birthcancer riskcancer therapycarcinogenesiscis-femalecis-maleclinical translationemotional distressexperimental studygender affirmationgender affirming hormonesimprovedmalemalignant breast neoplasmmouse modeltranscriptome sequencingtransfemininetransgendertreatment strategytumortumor growth
项目摘要
Project Summary
Our parent R21 grant (R21 CA267088) was to understand transfeminine patients’ risks and
benefits of continuing gender-affirming estrogen therapy (ET) during their breast cancer (BC)
treatment. Transfeminine individuals are assigned male at birth and most pursue ET to affirm their
feminine identity. As the transgender population increases, there will be a substantial number of
transgender individuals at risk for cancer as they age within the next 20 to 50 years. For
transfeminine patients diagnosed with BC, there is no clinical guideline whether they can continue
receiving ET during BC treatment, and whether ET affects their BC prognosis. The
discontinuation of gender-affirming hormones for a transgender individual is undesirable as it
greatly affects their emotional well-being and body image, and compounds their cancer-induced
emotional distress. In order to address the clinical question of the risks and benefits of
transfeminine patients continuing ET during BC treatment, the overall strategy of our parent R21
was to use three mouse models of BC—Pik3camut, Brca1mut, or Tp53mut—to understand the
effect of ET on BC treatment outcomes. We will compare tumor growth rates, breast histology,
and treatment outcomes between male mice that continue and discontinue ET during BC
treatment with alpelisib (for Pik3camut tumors), olaparib (for Brca mut tumors), or eribulin (for
Tp53mut tumors). In Year 1, we completed the experiments for Brca1mut tumors and olaparib
treatment. For the first half of Year 2, we will focus on completing experiments for Tp53mut
tumors to complement our Brca1mut findings. This will allow us to obtain a general overview of
how ET affects estrogen receptor negative (ER-) BC treatment. This supplement proposes three
additional molecular assays to explain our findings for Brca1mut and Tp53mut tumor models: 1) to
measure olaparib/eribulin levels in the tumors using mass spectrometry; 2) to profile ER- tumors
using RNASeq to identify gender and sex-hormone related molecular mechanisms influencing
BC treatment outcomes; and 3) assess the effect of gender and/or sex-hormone on tumor
immune contexture using multiplex immunofluorescence staining. Collectively, our work will
have direct and immediate clinical translation to inform ER- BC treatment options and decisions
for the transfeminine community. Our findings will also inform us why BC occurring in males are
more aggressive than in females, thus improving treatment strategies for cisgender men and
women with BC as well.
项目摘要
我们的母公司R21赠款(R21 CA 267088)是为了了解变性患者的风险,
在乳腺癌(BC)期间继续性别肯定雌激素治疗(ET)的益处
治疗变性人在出生时被分配为男性,大多数人追求ET以确认他们的性别。
女性身份随着跨性别人口的增加,将有大量的
跨性别者在未来20至50年内随着年龄的增长而有患癌症的风险。为
诊断为BC的跨女性患者,没有临床指南,他们是否可以继续
在BC治疗期间接受ET,以及ET是否影响BC预后。的
对变性人停止使用性别确认激素是不可取的,因为它
极大地影响了他们的情绪健康和身体形象,并加剧了他们的癌症诱导
情绪困扰为了解决风险和受益的临床问题,
跨女性患者在BC治疗期间继续ET,我们的父母R21的总体策略
使用三种BC-Pik 3camut、Brca 1 mut或Tp 53 mut小鼠模型,
ET对BC治疗结果的影响。我们将比较肿瘤生长率,乳腺组织学,
在BC期间继续和停止ET的雄性小鼠之间的治疗结果
用alpelisib(用于Pik 3camut肿瘤)、olaparib(用于Brca mut肿瘤)或eribulin(用于
TP 53 mut肿瘤)。在第一年,我们完成了Brca 1 mut肿瘤和奥拉帕尼的实验。
治疗在第二年的上半年,我们将专注于完成TP 53 mut的实验
肿瘤来补充我们的Brca 1 mut发现。这将使我们能够获得一个总体概述,
ET如何影响雌激素受体阴性(ER-)BC治疗。本补充建议三
其他分子测定来解释我们对Brca 1 mut和Tp 53 mut肿瘤模型的发现:1)
使用质谱法测量肿瘤中奥拉帕尼/艾日布林水平; 2)分析ER-肿瘤
使用RNASeq鉴定性别和性激素相关的分子机制,
BC治疗结果;以及3)评估性别和/或性激素对肿瘤的影响
使用多重免疫荧光染色进行免疫构造。我们的工作将
有直接和立即的临床翻译,以告知ER- BC治疗方案和决定
为变性人社区服务我们的研究结果还将告诉我们为什么BC发生在男性中,
比女性更具侵略性,从而改善了顺性别男性的治疗策略,
女性也有BC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yu Jing Jan Heng其他文献
Yu Jing Jan Heng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yu Jing Jan Heng', 18)}}的其他基金
Gender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment Outcomes
性别肯定睾酮疗法对乳腺癌风险和治疗结果的影响
- 批准号:
10912193 - 财政年份:2023
- 资助金额:
$ 8.99万 - 项目类别:
Gender-affirming estrogen therapy and breast cancer treatment outcome
性别肯定雌激素治疗和乳腺癌治疗结果
- 批准号:
10543116 - 财政年份:2021
- 资助金额:
$ 8.99万 - 项目类别:
Gender-affirming estrogen therapy and breast cancer treatment outcome
性别肯定雌激素治疗和乳腺癌治疗结果
- 批准号:
10350731 - 财政年份:2021
- 资助金额:
$ 8.99万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 8.99万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 8.99万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 8.99万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 8.99万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 8.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 8.99万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 8.99万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 8.99万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 8.99万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 8.99万 - 项目类别:
Miscellaneous Programs